tesetaxel + itraconazole

Tesetaxel + itraconazole is an investigational **oral combination drug** consisting of tesetaxel, a next-generation taxane (microtubule inhibitor) chemotherapy, and itraconazole, a broad-spectrum antifungal agent that additionally acts as a P-glycoprotein (P-gp/ABCB1) inhibitor and has anti-angiogenic properties. The rationale for combining these drugs is that itraconazole inhibits P-gp-mediated drug efflux and can reverse resistance to taxane chemotherapies such as tesetaxel by increasing the intracellular retention and cytotoxic effect of taxanes in cancer cells. Itraconazole may also provide additional anti-cancer effects via inhibition of the Hedgehog signaling pathway and angiogenesis. This combination is not approved as a single product but is under clinical investigation for the treatment of taxane-resistant or refractory cancers, particularly in solid tumors[2][3].